mCPP: an undesired addition to the ecstasy market.
Matthijs G. Bossong, Tibor M Brunt, J P Van Dijk, S M Rigter, J Hoek, H M J Goldschmidt, Raymond J.m. Niesink
Journal of psychopharmacology (Oxford, England) September 2010 DOI: 10.1177/0269881109102541 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | MDMA |
| Key points | Argues that mCPP is an undesired addition to the ecstasy market because its tablets are indistinguishable from MDMA tablets and user reports of its effects are predominantly negative. |
Abstract
A new ecstasy-like substance, meta-chlorophenylpiperazine (mCPP), has been detected in street drugs in the Netherlands. Theoretically, mCPP possesses the potential to become a non-neurotoxic alternative for methylenedioxymethamphetamine (MDMA), the regular psychoactive substance of ecstasy. Since its introduction on the Dutch market of synthetic drugs, the percentage of mCPP-containing tablets has increased, including both tablets that contain only mCPP and tablets containing a combination of mCPP and MDMA. These tablets occur in many different colours, shapes and sizes and with various logos, making it impossible to distinguish mCPP-containing tablets from regular MDMA tablets. In addition, the reports of users concerning the effects of mCPP are predominantly negative. All these aspects together lead to the conclusion that mCPP is an undesired addition to the ecstasy market from the user's perspective.